Advertisement

European Journal of Clinical Pharmacology

, Volume 28, Issue 3, pp 257–261 | Cite as

Mechanism of warfarin potentiation by amiodarone: Dose — and concentration — Dependent inhibition of warfarin elimination

  • S. Almog
  • N. Shafran
  • H. Halkin
  • P. Weiss
  • Z. Farfel
  • U. Martinowitz
  • H. Bank
Originals

Summary

Potentiation of the anticoagulant-effect of warfarin by amiodarone was studied in 30 patients. Thirteen received both drugs concurrently, and 17 received warfarin alone and the combination sequentially. Warfarin doses were adjusted to maintain the prothrombin time between 25–30% of control and its kinetics were compared to those in 20 control patients who received warfarin alone. Potentiation occurred in 28/30 patients, presenting as a 35%–65% reduction in the required dose of warfarin, and was correlated with the dose of amiodarone (r=0.77, p<0.01). The free warfarin fraction was not affected by amiodarone (1.8% vs 1.6% in the controls). Warfarin clearance was lower in amiodarone-treated patients than in the controls (1.4 vs 3.1 ml/min, p<0.01) with similar plasma concentrations (1.5 vs 1.2 µg/ml) despite administration of lower doses (23.3 vs 39 mg/week respectively). The amiodarone concentration was significantly correlated with the warfarin concentrations independent of the effect of amiodarone on the dose of warfarin. Amiodarone hat no effect on prothrombin other than through its actions on the dose and plasma concentration of warfarin. The mechanism of the amiodarone-warfarin interaction is pharmacokinetic through dose — and concentration — dependent inhibition of warfarin elimination.

Key words

amiodarone warfarin drug interaction metabolism inhibition plasma concentration pharmacokinetics 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Simpson WT (1979) Amiodarone in cardiac arrhythmias. International Congress Series No. 16, Royal Society of Medicine. Grune and Stratton, New York, p 50Google Scholar
  2. 2.
    Martinowitz U, Rabinovich J, Goldfarb D, Many A, Bank H (1981) Interaction between warfarin sodium and amiodarone (letter). N Engl J Med 304: 671–672Google Scholar
  3. 3.
    Rees A, Dalal JJ, Reid PG, Henderson AH, Lewis MJ (1981) Dangers of amiodarone and anticoagulant treatment. Br Med J 282: 1756–1757Google Scholar
  4. 4.
    Serlin MJ, Sibeon RG, Green GJ (1981) Dangers of amiodarone and anticoagulant treatment (letter). Br Med J 283: 58Google Scholar
  5. 5.
    Hamer A, Peter T, Mandel WJ, Scheinman MM, Weiss D (1982) The potentiation of warfarin anticoagulation by aminodarone. Circulation 65: 1025–1029Google Scholar
  6. 6.
    Forman WB, Shales J (1978) Comparison of high-performance liquid chromatography and a spectrophotometric technique for determining plasma warfarin. J Chromatogr. 146: 522–526Google Scholar
  7. 7.
    Lesko LJ, Marion A, Canada AT, Haffajee C (1981) High pressure liquid chromatography of amiodarone in biological fluids. J Pharm Sci 70: 1366–1367Google Scholar
  8. 8.
    Rowland M, Tozer TN (1980) Clinical pharmacokinetics. Concepts and applications, Chapter 6. Hepatic clearance and elimination. Lea and Febiger, Philadelphia, p 60Google Scholar
  9. 9.
    Haffajee CI, Love JC, Alpert JS, Asdourian GK, Sloan KC (1983) Efficacy and safety of long term amiodarone in treatment of cardiac arrhythmias. Am Heart J 106: 935–943Google Scholar
  10. 10.
    Marcus FI (1983) Drug interactions with amiodarone. Am Heart J 106: 924–929Google Scholar
  11. 11.
    Shepard AMM, Hewick DS, Moreland TA, Stevenson IH (1977) Age as a determinant of sensitivity to warfarin. Br J Clin Pharmacol 4: 315–320Google Scholar
  12. 12.
    Yacobi A, Udall JA, Levy G (1976) Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect. Clin Pharmacol Ther 19: 552–558Google Scholar
  13. 13.
    Mungall D, Ludden TM, Marshall J, Crawford M, Hawkins D (1984) Relationships between steady-state warfarin concentrations and anticoagulant effect. Clin Pharmacokinet 9 [Suppl 1]: 99–100Google Scholar

Copyright information

© Springer-Verlag 1985

Authors and Affiliations

  • S. Almog
    • 1
    • 2
  • N. Shafran
    • 1
    • 2
  • H. Halkin
    • 1
    • 2
  • P. Weiss
    • 1
    • 2
  • Z. Farfel
    • 1
    • 2
  • U. Martinowitz
    • 1
    • 2
  • H. Bank
    • 1
    • 2
  1. 1.Department of Medicine, Sheba Medical CenterAnticoagulation Clinic and Clinical Pharmacology UnitTel HashomerIsrael
  2. 2.Tel Aviv University School of MedicineIsrael

Personalised recommendations